+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monoclonal Antibody Therapeutics Market - Global Forecast 2026-2032- Product Image
Monoclonal Antibody Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Monoclonal Antibody Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829819
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Monoclonal Antibody Therapeutics Market is projected to reach USD 310.39 Billion in 2026. It is expected to continue growing at a CAGR of 13.71%, reaching USD 672.50 Billion by 2032.

Monoclonal antibody therapeutics remain one of the most clinically validated and commercially important classes in biologic medicines, with established use across oncology, autoimmune disorders, inflammatory diseases, infectious disease prevention, ophthalmology, neurology, and transplant medicine. Their strategic strength is supported by decades of regulatory experience, expanding indication coverage, and the proven ability of antibodies to bind disease-relevant targets with high specificity.

Growth is being shaped by the shift from first-generation murine and chimeric antibodies to humanized, fully human, bispecific, antibody-drug conjugate, Fc-engineered, and subcutaneous formulations. Industry adoption is also being reinforced by biosimilar competition, payer demand for value, and continued investment in biologics manufacturing capacity, cold-chain logistics, pharmacovigilance, and real-world evidence generation.

Transformative Shifts in the Monoclonal Antibody Landscape

The monoclonal antibody therapeutics landscape is transforming from a product-by-product innovation cycle into a platform-led ecosystem. Oncology remains a leading field, but immune-mediated diseases, Alzheimer’s disease, respiratory syncytial virus prevention, migraine, hypercholesterolemia, and rare diseases demonstrate the broadening clinical utility of antibody-based therapies.

Competitive differentiation is increasingly driven by mechanism of action, route of administration, dosing interval, biomarker strategy, safety profile, and manufacturability. Subcutaneous delivery, longer half-life designs, dual-targeting antibodies, and antibody-drug conjugates are improving patient convenience and clinical outcomes, while biosimilars are reshaping pricing and access in mature therapeutic areas such as oncology and immunology.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across discovery, development, manufacturing, and commercialization of monoclonal antibody therapeutics. AI-enabled protein modeling, antibody sequence optimization, developability screening, and epitope prediction help researchers prioritize candidates with stronger binding profiles, lower aggregation risk, and more favorable manufacturability attributes before costly wet-lab validation.

In clinical development, machine learning supports trial site selection, patient stratification, biomarker discovery, adverse event signal detection, and real-world evidence analysis. In manufacturing, AI-assisted process analytics, predictive maintenance, and digital twins are improving batch consistency, reducing deviations, and supporting quality-by-design practices. The greatest value is emerging where AI is paired with validated biological data, rigorous regulatory documentation, and human scientific oversight.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is gaining strategic importance through expanding biologics manufacturing, rising cancer and autoimmune disease diagnosis, and national policies that encourage biosimilar uptake and domestic innovation. China, India, Japan, South Korea, Australia, and ASEAN markets are becoming more influential across clinical development, contract manufacturing, and commercial expansion, supported by growing clinical trial activity and improving regulatory alignment with international standards.

North America remains a core innovation and commercialization hub, led by the United States with deep venture funding, advanced academic research, FDA regulatory experience, established specialty pharmacy infrastructure, and broad biologics adoption. Canada contributes through clinical research networks and public reimbursement frameworks that increasingly assess cost effectiveness. Latin America is advancing through expanding oncology access, biologics procurement reform, and biosimilar adoption, with Brazil and Mexico serving as central markets for regional commercialization.

Europe benefits from the European Medicines Agency’s mature biosimilar pathway, national health technology assessment systems, and strong pharmaceutical manufacturing clusters, making the region highly influential in clinical evidence standards and post-authorization safety monitoring. The Middle East is investing in specialty care infrastructure, oncology centers, and biologics procurement modernization, particularly in GCC countries. Africa remains earlier in adoption, but demand is rising as cancer care capacity, diagnostic access, cold-chain systems, and public-private healthcare investment expand.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are increasingly relevant for monoclonal antibody therapeutics because governments are expanding universal health coverage, oncology services, and biologics procurement, while regulatory reliance pathways and regional cooperation are helping accelerate access. GCC countries are prioritizing specialty care, health system modernization, cancer treatment capacity, and local pharmaceutical capability, creating opportunities for premium biologics, biosimilars, and hospital-based infusion services.

The European Union remains a benchmark for biosimilar policy, pharmacovigilance, centralized regulatory review, and health technology assessment, supporting competition while maintaining strict quality standards. BRICS countries represent a high-priority access frontier due to large patient populations, rising biologics manufacturing capability, expanding clinical trial activity, and government interest in reducing dependence on imported high-cost medicines.

G7 markets continue to shape global standards in clinical evidence, pricing, reimbursement, intellectual property, pharmacovigilance, and biologics quality. NATO-aligned countries, many of which overlap with high-income European and North American markets, are also strengthening supply resilience, domestic biomanufacturing, medicine security, and critical healthcare preparedness after pandemic-era supply disruptions.

Key Country Insights Across Major Monoclonal Antibody Markets

The United States leads global monoclonal antibody commercialization through strong FDA approvals, specialty pharmacy networks, payer management, high clinical trial density, and advanced biomarker-enabled care pathways. Canada emphasizes health technology assessment and provincial reimbursement, while Mexico is expanding specialty medicine access through public and private healthcare channels. Brazil remains Latin America’s most significant biologics market, supported by oncology demand, biosimilar adoption, and local production initiatives.

The United Kingdom, Germany, France, Italy, and Spain are major European markets where reimbursement decisions, biosimilar tendering, hospital procurement, and clinical guideline adoption determine uptake. Germany’s strong biopharmaceutical base and early market access pathway are influential, while France, Italy, and Spain leverage national procurement and hospital systems to manage biologics spending. Russia has supported domestic biologics production, though market access is affected by geopolitical and supply-chain constraints.

China has become a major force in antibody R&D, clinical trials, biosimilars, and domestic commercialization, supported by regulatory reforms and expanding oncology care. India is a leading biosimilar and biomanufacturing participant with cost-efficient development capabilities and increasing demand for affordable biologics. Japan’s market is driven by aging demographics, regulatory quality, and high-value specialty care, while Australia supports advanced clinical research and reimbursement through evidence-based assessment. South Korea is globally recognized for biosimilar manufacturing, contract development, and biologics export strength.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize differentiated antibody platforms with clear clinical value over incremental products in crowded indications. Stronger outcomes can be achieved by aligning target selection, biomarker strategy, patient segmentation, companion diagnostic planning, and health economic evidence early in development.

Organizations should invest in flexible biomanufacturing, high-yield cell line development, continuous processing, analytical characterization, and resilient supply chains to manage demand volatility and quality expectations. Commercial teams should prepare for biosimilar competition through lifecycle management, subcutaneous formulations, patient support services, physician education, and evidence packages that demonstrate real-world effectiveness, safety, and budget impact.

AI adoption should be governed by transparent validation, data lineage, cybersecurity safeguards, model monitoring, and regulatory-ready documentation. Partnerships with academic centers, contract development and manufacturing organizations, diagnostic specialists, healthcare providers, and regional distributors can accelerate global reach while reducing operational, regulatory, and access-related risk.

Research Methodology

This executive summary is developed using a structured secondary research approach anchored in publicly available regulatory, clinical, scientific, and healthcare policy sources. Core inputs include drug approval databases, clinical trial registries, peer-reviewed literature, health authority communications, reimbursement frameworks, pharmacovigilance resources, biosimilar policy documents, and recognized industry publications.

Insights are triangulated across therapeutic area trends, regional policy developments, biologics manufacturing capacity, biosimilar adoption, clinical trial activity, regulatory pathways, and technology shifts such as AI-enabled discovery and process analytics. The methodology emphasizes evidence consistency, source credibility, relevance to monoclonal antibody therapeutics, and exclusion of unsupported claims, market sizing, market share, and forecasting statements.

Conclusion

Monoclonal antibody therapeutics are positioned for continued strategic importance as healthcare systems seek targeted, evidence-based treatments for high-burden diseases. The sector’s next phase will be defined by differentiated modalities, biosimilar-driven access, regional manufacturing expansion, and stronger integration of diagnostics, data science, pharmacovigilance, and real-world evidence.

Organizations that combine scientific innovation with scalable manufacturing, payer-aligned value evidence, robust quality systems, and disciplined AI implementation will be best placed to compete. As global demand expands across oncology, immunology, infectious disease prevention, neurology, and rare diseases, leadership will depend on delivering clinically meaningful outcomes while improving affordability, reliability, and patient access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Monoclonal Antibody Therapeutics Market, by Antibody Type
7.1. Introduction
7.2. Chimeric
7.3. Fully Human
7.4. Humanized
7.5. Murine
8. Monoclonal Antibody Therapeutics Market, by Indication
8.1. Introduction
8.2. Autoimmune Disorders
8.2.1. Inflammatory Bowel Disease
8.2.2. Multiple Sclerosis
8.2.3. Psoriasis
8.2.4. Rheumatoid Arthritis
8.3. Cardiovascular Conditions
8.4. Infectious Diseases
8.4.1. COVID-19
8.4.2. HIV
8.4.3. Respiratory Syncytial Virus
8.5. Neurological Disorders
8.5.1. Alzheimer’s Disease
8.5.2. Multiple Sclerosis
8.6. Oncology
8.6.1. Hematological Malignancies
8.6.1.1. Leukemia
8.6.1.2. Multiple Myeloma
8.6.1.3. Non-Hodgkin Lymphoma
8.6.2. Solid Tumors
9. Monoclonal Antibody Therapeutics Market, by Molecular Target
9.1. Introduction
9.2. CD20
9.3. EGFR
9.4. HER2
9.5. TNF Alpha
10. Monoclonal Antibody Therapeutics Market, by Production Technology
10.1. Introduction
10.2. Hybridoma
10.3. Recombinant DNA
10.4. Transgenic Animal
11. Monoclonal Antibody Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intravenous
11.4. Subcutaneous
12. Monoclonal Antibody Therapeutics Market, by Therapy Type
12.1. Introduction
12.2. Combination Therapy
12.3. Monotherapy
13. Monoclonal Antibody Therapeutics Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Diagnostic Laboratories
13.4. Hospitals
13.5. Specialty Centers
14. Monoclonal Antibody Therapeutics Market, by Distribution Channel
14.1. Introduction
14.2. Offline Pharmacy
14.2.1. Hospital Pharmacy
14.2.2. Retail Pharmacy
14.2.3. Specialty Pharmacy
14.3. Online Pharmacy
15. Monoclonal Antibody Therapeutics Market, by Region
15.1. Asia-Pacific
15.2. Europe
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Monoclonal Antibody Therapeutics Market, by Group
16.1. NATO
16.2. G7
16.3. BRICS
16.4. European Union
16.5. ASEAN
16.6. GCC
17. Monoclonal Antibody Therapeutics Market, by Country
17.1. China
17.2. United States
17.3. India
17.4. Japan
17.5. Germany
17.6. United Kingdom
17.7. Australia
17.8. South Korea
17.9. France
17.10. Canada
17.11. Italy
17.12. Brazil
17.13. Mexico
17.14. Russia
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AbbVie Inc.
19.2. Amgen Inc.
19.3. Astellas Pharma Inc.
19.4. Bayer AG
19.5. Biogen Inc.
19.6. Bristol-Myers Squibb Company
19.7. Corvidia Therapeutics Inc. by Novo Nordisk A/S
19.8. Eli Lilly and Company
19.9. F. Hoffmann-La Roche Ltd
19.10. GenScript
19.11. Gilead Sciences, Inc
19.12. GlaxoSmithKline Plc
19.13. Johnson & Johnson
19.14. Merck Sharp & Dohme Corp.,
19.15. Novartis International AG
19.16. Pfizer Inc
19.17. Regeneron Pharmaceuticals, Inc.
19.18. Sanofi S.A
19.19. Takeda Pharmaceutical Company Limited
19.20. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FULLY HUMAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FULLY HUMAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FULLY HUMAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MURINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MURINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MURINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CARDIOVASCULAR CONDITIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CARDIOVASCULAR CONDITIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CARDIOVASCULAR CONDITIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ALZHEIMER’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ALZHEIMER’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ALZHEIMER’S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CD20 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CD20 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CD20 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL EGFR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL EGFR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL EGFR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HER2 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HER2 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HER2 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL TNF ALPHA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TNF ALPHA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TNF ALPHA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HYBRIDOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HYBRIDOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HYBRIDOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RECOMBINANT DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL RECOMBINANT DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL RECOMBINANT DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TRANSGENIC ANIMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL TRANSGENIC ANIMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL TRANSGENIC ANIMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 159. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 161. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 162. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 163. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 164. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 165. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 166. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 167. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 168. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 171. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 189. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 192. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 193. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 194. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 195. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 196. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 197. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 204. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 205. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 206. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 207. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 208. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 209. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 210. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 211. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 212. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 213. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 214. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 216. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 220. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 221. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 222. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 223. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 224. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 225. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 226. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 227. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 229. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 234. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 237. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 238. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 239. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 240. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 241. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 242. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 243. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 244. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 245. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 247. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 250. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 252. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 253. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 254. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 255. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 256. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 257. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 258. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 259. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 262. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 265. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 266. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 267. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 268. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 269. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 270. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 271. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 272. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 273. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 274. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 275. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 277. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 290. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 295. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 296. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 297. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 298. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 299. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 300. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 301. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 302. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 303. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 304. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 305. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 307. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 310. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 311. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 312. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 313. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 314. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 315. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 316. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 317. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 318. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2017-2032 (USD MILLION)
TABLE 319. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 320. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 321. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 322. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 324. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 325. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 326. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2017-2032 (USD MILLION)
TABLE 328. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 329. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 330. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 331. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 332. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 333. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 334. CHINA MONOCLONAL ANTIB

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Corvidia Therapeutics Inc. by Novo Nordisk A/S
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Gilead Sciences, Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.,
  • Novartis International AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 310.39 Billion
Forecasted Market Value ( USD ) by 2032 $ 672.5 Billion
Compound Annual Growth Rate13.7%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Antibody Production - Global Strategic Business Report - Product Image

Antibody Production - Global Strategic Business Report

  • Report
  • 392 Pages
  • Global
From
Biopharmaceutical Market Size, Share, Trends and Forecast by Indication, Class, and Region, 2026-2034 - Product Image

Biopharmaceutical Market Size, Share, Trends and Forecast by Indication, Class, and Region, 2026-2034

  • Report
  • 142 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034 - Product Image

Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034

  • Report
  • 136 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.